CATALENT, INC. (NYSE:CTLT) Files An 8-K Regulation FD Disclosure
Item 7.01
|
Regulation FD Disclosure.
|
presentation materials that will be included in an investor
presentation to be delivered by the Registrant at an investor
conference scheduled to be held on January 9, 2017. These
materials are attached to this Current Report on Form 8-K as
Exhibit 99.1 and are incorporated by reference herein in their
entirety.
that are not prepared in accordance with those accounting
principles generally accepted in the United States (GAAP). Please
refer to the materials, including its Appendix, for disclosures
regarding those Non-GAAP Measures, including reconciliations to
the most directly comparable GAAP measures.
information under this Item 7.01 shall be deemed furnished to the
SEC and not be deemed filed with the SEC for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section.
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Please see the
materials for information regarding such forward-looking
statements, including meaningful cautionary statements relating
thereto.
|
Exhibit No.
|
Description
|
|
99.1
|
Presentation materials dated January 9, 2017
|
About CATALENT, INC. (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services. CATALENT, INC. (NYSE:CTLT) Recent Trading Information
CATALENT, INC. (NYSE:CTLT) closed its last trading session up +0.03 at 26.91 with 654,131 shares trading hands.